InvestorsHub Logo
Followers 4
Posts 524
Boards Moderated 0
Alias Born 04/22/2015

Re: shermann7 post# 76550

Monday, 07/30/2018 11:15:16 PM

Monday, July 30, 2018 11:15:16 PM

Post# of 108192
Amgen is a potential buyer. But we will need more promising results from the collaboration.

Another potential buyer is AZN. But durvalumab is a big issue with the combo. This inhibitor pretty much failed all the way and they are desperate to make progress as they have spent so much money on it.

TPIV has a combo study with durvalumab too funded by AZN. Results pending but seemed not promising.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News